Genflow Biosciences CEO on Acuitas collaboration: non-dilutive growth catalyst

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire joined Proactive's Stephen Gunnion to discuss a landmark collaboration with Acuitas Therapeutics, the lipid nanoparticle specialist whose technology underpinned some of the most successful COVID-19 vaccines ever made. Leire described it as one of the most significant partnerships Genflow has signed, giving the company access to the gold standard in mRNA delivery technology - fully funded by Acuitas, with no cash cost and no dilution to shareholders. The collaboration will combine Genflow's proprietary SIRT6 payload with Acuitas' clinically validated LNP platform, generating preclinical data to support future clinical development and partnering discussions. Leire positioned the deal as a potential inflexion point, transitioning Genflow from a science story into a tangible clinical and commercial opportunity. For more videos like this, visit Proactive's YouTube channel, give this video a like, subscribe to the channel, and enable notifications so you never miss an update. #GenflowBiosciences #EricLeire #BiotechNews #SIRT6 #mRNA #LNP #Acuitas #BiotechInvesting #HealthcareInnovation #DrugDevelopment #ClinicalTrials #LifeSciences #InvestingNews #ProactiveInvestors